RECEIVED CENTRAL FAX CENTER

PATENT

JUN 0 6 2008

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application: Willem Ferdinand Nieuwenhuizen et al.

Application No. : 10

10/592,994 March 23, 2007

Filed : Confirmation No. :

: 8473

For

USE OF SPHINGOLIPIDS IN THE TREATMENT AND PREVENTION OF TYPE 2 DIABETES MELLITUS,

INSULIN RESISTANCE AND METABOLIC SYNDROME

Examiner : Timothy P. Thomas

Attorney's Docket : VER-209XX

TC Art Unit: 1614

By:

Charles L. Gagnebin III Registration No. 25,467 Attorney for Applicant(s)

RESPONSE

Via Facsimile Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In response to the Office Action subject to Restriction
Requirement dated March 27, 2008, Applicants elect for present
prosecution the claims of Group IV, Claims 9-10, drawn to a food
item with enhanced levels of a sphingolipid. Applicants also

_ 1 _ 06/09/2008 VBUII1 00000005 230804 10592994 01 FC:1252 460.00 DA

WEINGARTEN, SCHURGIN, GAGNEBIN & LEBOVITE LLP TEL (617) 542-2290

JUN 0 6 2008

Application No. 10/592,994 Filed: March 23, 2007 TC Art Unit: 1614

Confirmation No.: 8473

elect under option (i-a) Phytosphingosine as a single sphingolipid. This election is with traverse because examination of all of the claims is not seen as imposing an undue burden on the Examiner.

Applicants reserve all rights to the unelected claims for future prosecution but hereby authorize the Examiner to cancel them as he deems necessary for the prosecution of the present application.

Respectfully submitted,

WILLEM FERDINAND NIEUWENHUIZEN ET AL.

Ву

Registration No. 35467
Attorney for Applicant(s)

WEINGARTEN, SCHURGIN,
GAGNEBIN & LEBOVICI LLP
Ten Post Office Square
Boston, MA 02109

Telephone: (617) 542-2290 Telecopier: (617) 451-0313

CLG/dkh/367818.1